0001393905-18-000354.txt : 20181206 0001393905-18-000354.hdr.sgml : 20181206 20181206172742 ACCESSION NUMBER: 0001393905-18-000354 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181206 FILED AS OF DATE: 20181206 DATE AS OF CHANGE: 20181206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PORTAGE BIOTECH INC. CENTRAL INDEX KEY: 0001095435 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30314 FILM NUMBER: 181221649 BUSINESS ADDRESS: STREET 1: 47 AVENUE ROAD STREET 2: SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5R 2G3 BUSINESS PHONE: 416-929-1806 MAIL ADDRESS: STREET 1: 47 AVENUE ROAD STREET 2: SUITE 200 CITY: TORONTO STATE: A6 ZIP: M5R 2G3 FORMER COMPANY: FORMER CONFORMED NAME: BONTAN CORP INC DATE OF NAME CHANGE: 20030421 FORMER COMPANY: FORMER CONFORMED NAME: DEALCHECK COM INC DATE OF NAME CHANGE: 19990921 6-K 1 ptgef_6k.htm REPORT OF FOREIGN PRIVATE ISSUER 6K



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


Form 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934


For the month of December 2018

(December 6, 2018)

Commission File Number 0-30314


PORTAGE BIOTECH INC.

(Translation of registrant's name into English)


47 Avenue Rd., Suite 200, Toronto, Ontario, Canada M5R 2G3

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F [X]  Form 40-F [  ]


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes [  ]  No [X]


If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82- ______________.








Portage Shares to Resume Trading; SalvaRx Acquisition Meeting Materials mailed and filed on SEDAR


Toronto, Ontario, December 6, 2018 (PBT.U: CSE, PTGEF: OTC Markets) – Further to its news release of November 27, 2018, Portage Biotech Inc. ("Portage" or the "Company") is pleased to announce that its common shares will resume trading at the open on CSE tomorrow, December 7, 2018 with trading on OTC expected to resume shortly thereafter.


The mailing of shareholder meeting materials regarding the acquisition of SalvaRx Limited from SalvaRx Group plc has been completed. Copies of the meeting materials have been posted to SEDAR, the CSE website and Portage’s corporate website.


Completion of the SalvaRx acquisition remains subject to shareholder and CSE approval.


For further information, please contact:


Kam Shah, CFO

Tel: (416) 929-1806

ks@portagebiotech.com


Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.


This news release may contain forward looking statements concerning future operations of Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company’s future plans and operations, including management’s assessment of the Company’s expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company’s control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.










2



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Dated:  December 6, 2018


PORTAGE BIOTECH INC.


By: /s/ Kam Shah

Kam Shah

Chief Financial Officer




























3